| Zhu (2004) China | 56 | A: Modified SCRTdose NRPO (n=36) | B: Loratadine 10mg qd PO.Ephedrine, Dexamethasone nasal drops tid (n=20) | 15 days | 1. Effective rate | 1. No significant difference between the two groupsA: 30/36 B: 14/20 | NR |
| A: 16/20 B: 9/11 |
| NR |
| Jin (2010) China | 30 | A: SCRT150mlbid PO(n=15) | B: Loratadine 10mg qd PO (n=15) | 14 days | 1. Changes in the symptom score | 1. A<B (p<0.01)A: 1.66±0.95 B: 3.31±1.13 | NR |
| A: 7/8 B: 8/7 |
| A: 36B: 38 |
| Chen (2010) China | 86 | A: SCRTdose NRbid PO(n=43) | B: Loratadine 10mg qd PO (n=43) | 3 weeks | 1. The level of eosinophil ① after treatment ② after 2 months2. Serum IL-4 levels after 2 months | 1. ① A<B (p<0.05) A: 14/43 B: 24/43 ② A<B (p<0.01) A: 16/43 B: 30/432. A<B (p<0.01) A: 14.21±3.37 B: 18.14±3.00 | NR |
| A: 24/19 B: 23/20 |
| A: 34.40±9.90B: 32.15±9.48 |
| Chi (2012) China | 60 | A: Modified SCRT125-150mlbid PO(n=30) | B: Loratadine 5mg qd PO (n=30) | 4 weeks | 1. Effective rate2. Changes in the symptom score | 1. A>B (p<0.05) A: 13/30 B: 3/302. No significant difference between the two groups A: 3.18±0.96 B: 3.26±1.11 | NR |
| A: 15/15 B: 13/17 |
| A: 25.4±6.1B: 25.3±6.2 |
| Chen (2012) China | 106 | A: SCRTdose NRbid PO(n=53) | B: Loratadine 10mg qd PO (n=53) | 3 weeks | 1. Effective rate2. Changes in the symptom score3. Changes in physical sign score4. Recurrence rate ① after 3 months ② after 6 months | 1. No significant difference between the two groups A: 46/53 B: 43/532. Nasal obstruction : A>B (p<0.05)3. A>B (p<0.05)4. A<B (p<0.05) ① A: 4/53 B: 14/53 ② A: 7/53 B: 18/53 | NR |
| A: 26/27 B: 28/25 |
| A: 33.20±9.56B: 31.45±9.12 |
| Liu (2014) China | 59 | A: Modified SCRTdose NRbid PO(n=30) | B: Loratadine 10mg PO(n=29) | 3 weeks | 1. Effective rate ① after treatment ② after 2 weeks2. Changes in the symptom score3. Changes in physical sign score | 1. ① No significant difference between the two groups A: 19/30 B: 17/29 ② A>B (p<0.01) A: 14/30 B: 1/292. A<B3. A<B | NR |
| NR |
| NR |
| Li (2015) China | 128 | A: Modified SCRT150mltid PO(n=64) | B: conventional medicine PO (n=64) | 4 weeks | 1. VAS (after 16 weeks)2. RQLQ (after 16 weeks) | 1. No significant difference between the two groups A: 5.303±1.862 B: 5.203±1.7202. A>B (p<0.05) A: 84.472±6.875 B: 78.673±8.566 | A: Sleepiness(1), Nasal cavity and oropharynx dryness(2), General weakness(1)B: Insomnia(2), Dry mouth(2), Gastric discomfort(2) |
| A: 35/29 B: 28/36 |
| A: 36.112±11.495B: 38.083±12.106 |
| Zhang (2016) China | 120 | A: Modified SCRTdose NRbid PO(n=60) | B: Loratadine 10mgqd PO(n=60) | Unknown | 1. Effective rate2. The number of rhinitis episodes within 1 year3. Symptom and physical sign score4. Treatment satisfaction | 1. A>B (p<0.05) A: 59/60 B: 48/602. A<B (p<0.05) A: 2.83±1.26 B: 4.30±1.213. A<B (p<0.05) A: 1.54±0.09 B: 4.04±1.194. A>B (p<0.05) A: 58/60 B: 47/60 | NR |
| A: 36/24 B: 37/23 |
| A: 42.65±7.46B: 41.49±7.95 |
| Du (2017) China | 60 | A: Modified SCRT 300mlbid PO(n=30) | B: Desloratadine 5mgqd PO(n=30) | 2 weeks | 1. VAS1. RQLP | 1. No significant difference between the two groups A: 5.65±1.32 B: 5.58±1.452. A>B (p<0.05) A: 85.01±6.74 B: 77.68±8.95 | A: Insomnia(1), Dry mouth(2), General weakness(1)B: Insomnia(3), Dry mouth(7), General weakness(3) |
| A: 16/14 B: 15/15 |
| A: 42.12±2.14B: 42.32±2.51 |
| Chen (2017) China | 60 | A: Modified SCRT200mlbid PO(n=30) | B: Cetirizine 10mg qd PO. Budesonide nasal spray bid(n=30) | 30 days | 1. Effective rate2. Symptom score3. IgE test negative rate after 6 months of treatment | 1. A>B (p<0.05) A: 28/30 B: 23/302. Ap<B (pp<0.05)3. A>B (pp<0.05) A: 24/30 B: 14/30 | NR |
| Total: 32/28 |
| Total: 38.8±9.5 |
| Wang (2018) China | 100 | A: Modified SCRT200mlbid PO(n=50) | B: Loratadine 10mg qd PO (n=50) | Unknown | 1. Effective rate2. Symptom and physical sign score3. Recurrence rate (during 1 year) | 1. A>B (p<0.05) A: 49/50 B: 39/502. A<B (p<0.05) A: 2.458±1.037 B: 4.629±1.7253. A<B (p<0.05) A: 5/50 B: 23/50 | NR |
| A: 30/20 B: 28/22 |
| A: 29.5±2.4B: 29.3±2.1 |
| Xu (2018) China | 278 | A: SCRTdose NRbid PO(n=139) | B: Budesonide nasal spray bid,Loratadine10mg qd PO(n=139) | 7 days | 1. Recurrence rate ① after 3 months ② after 1 year ③ after 3 years | 1. A<B ① A: 11/139 B: 15/139 ② A: 5/139 B: 24/139 ③ A: 17/139 B: 41/139 | NR |
| A: 53/86 B: 49/90 |
| A: 31.0±3.5 B: 30.0±3.3 |
| Li (2005) China | 80 | A: Modified SCRT150ml bid PO + Routine western medicine PO(n=42) | B: Routine western medicine PO(n=38) | 14 days | 1. Effective rate2. IgE in the serum3. Eosinophil counts | 1. No significant difference between the two groups A: 40/42 B: 35/382. A<B (p<0.05) A: 0.013±0.008 B: 0.014±0.0073. No significant difference between the two groups A: 0.26±0.16 B: 0.27±0.15 | NR |
| A: 22/20 B: 20/18 |
| A: 38B: 36 |
| Zhu (2011) China | 104 | A: SCRT 1ml/age(max 10ml) tid PO + Loratadine5mg or 10mg qd PO(n=56) | B: Loratadine5mg or 10mgqd PO(n=48) | 2 weeks | 1. Effective rate | 1. A>B (p<0.05) A: 54/56 B: 36/48 | A,B:No serious adverse events |
| A: 32/24 B: 26/22 |
| NR |
| Chai (2013) China | 35 | A: Modified SCRT150ml bid PO + Routine western medicine PO(n=18) | B: Routine western medicine PO(n=17) | 20-30 days | 1. Effective rate2. IgE in the serum | 1. A>B (p<0.05) A: 16/18 B: 14/172. A<B (p<0.05) A: 0.012±0.008 B: 0.014±0.007 | NR |
| A: 12/6 B: 10/7 |
| A: 39B: 36 |
| Wu (2015) China | 90 | A: Modified SCRT150ml bid PO + Mometasone furoate nasal spray bid(n=45) | B: Mometasone furoate nasal spray bid(n=45) | 8 weeks | 1. Effective rate2. Recurrence rate (after half a year of treatment) | 1. A>B (p<0.05) A: 42/45 B: 35/452. A<B (p<0.05) A: 8/42 B: 14/35 | A: Nausea(3), Nasal dryness(2), Hoarseness(1),B: Nasal dryness(2), Hoarseness(1) |
| A: 24/21B: 26/19 |
| A: 38.1±5.2B: 37.7±4.9 |
| Zhang (2015) China | 80 | A: SCRT 150mlbid PO + Budesonide nasal spray bid(n=40) | B: Budesonide nasal spray bid(n=40) | 4 weeks | 1. Symptom and physical sign score2. Effective rate3. Serum ① IL-6, ② IL-8, ③ IL-10 level | 1. A<B (p<0.05) A: 3.13±0.68 B: 5.36±1.122. A>B (p<0.05) A: 37/40 B: 30/403.① A<B (p<0.05) A: 102.18±6.72 B: 145.26±9.27 ② A<B (p<0.05) A: 112.15±8.65 B: 136.53±9.17 ③ A>B (p<0.05) A: 17.13±3.28 B: 14.56±3.15 | NR |
| A: 17/23B: 19/21 |
| A: 34.5±7.2B: 35.1±6.8 |
| Kim (2019) Korea | 154 | A: SCRT3gtid PO(n=78) | B: placebo 3g tid PO (n=76) | 4 weeks | 1. Change in the total nasal symptoms score2. Change in the RQLQ score3. Changes in total ① serum IgE ② eosinophil counts ③ cytokines levels4. Nasal endoscopy index | 1. A>B (p<0.05) ① At week 2: A: -2.40±1.37 B: -1.57±0.96 ② At week 4: A: -3.07±1.53 B: -2.10±1.022. At week 4: A>B (p<0.05) A: -35.13±26.82 B: -25.73±29.98 3. No significant differences between two groups ① A: 7.35±52.79 B: 38.20±249.50 ② A: -5.66±98.66 B: 7.60±104.97 ③ IL-4 A: 3.19±14.65 B: 9.17±17.00 IL-5 A: -2.92±1.38 B: -3.13±1.08 IL-8 A: -1.47±1.79 B: -2.33±3.714. TNSS changes showed negative correlations with heat scores and positive correlations with cold scores (no significant difference) | No significant difference between the two groups in the proportion of reported AEs, and no serious AEs were reported |
| A: 50/28B: 44/32 |
| A: 33.68±9.78B: 34.36±11.31 |